Literature DB >> 2968406

Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein.

M Ogasawara1, G J Cianciolo, R Snyderman, M Mitani, R A Good, N K Day.   

Abstract

A synthetic 17 amino acid peptide (CKS-17) homologous to a highly conserved region of human and animal retroviral transmembrane proteins was investigated for its influence on the in vitro production of IFN-gamma from human peripheral mononuclear cells. The results showed that CKS-17 coupled to a carrier protein, BSA, inhibited production of IFN-gamma in a dose-dependent manner. Controls, consisting of BSA, which had undergone the coupling procedure or neurotensin coupled to BSA in an identical manner as CKS-17, showed no such inhibition. Reduction in IFN-gamma production could not be attributed to decreased viability of cells, delay of IFN-gamma production or to involvement of suppressor cells. Moreover, inhibition of IFN-gamma production was not related to the inhibition of DNA synthesis. The inhibition appeared to be a direct effect of CKS-17 on IFN-gamma-producing cells. Kinetic studies revealed that this suppression occurred when CKS-17 was introduced to the culture concurrent with or within 48 h after introduction of IFN inducers. Preincubation experiments showed that the presence of CKS-17 in the culture medium was not necessary to exert its inhibitory effect. These results suggest that a portion of retroviral envelope proteins possess important immunomodulatory actions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968406

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Inhibition of lymphoproliferation and protein kinase C by synthetic peptides with sequence identity to the transmembrane and Q proteins of visna virus.

Authors:  C L Ruegg; J E Clements; M Strand
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

2.  Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II.

Authors:  C L Ruegg; C R Monell; M Strand
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

3.  Synthetic peptide homologous to the envelope proteins of retroviruses shares a cross-reacting epitope with the CD4 receptor.

Authors:  J Rothmann; N F Hassan; D E Campbell; N Kamani; S D Douglas
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

4.  Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products.

Authors:  M Nelson; D S Nelson; G J Cianciolo; R Snyderman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer.

Authors:  P J Simons; R A Oostendorp; M P Tas; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

6.  The YXXL signalling motifs of the bovine leukemia virus transmembrane protein are required for in vivo infection and maintenance of high viral loads.

Authors:  L Willems; J S Gatot; M Mammerickx; D Portetelle; A Burny; P Kerkhofs; R Kettmann
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.

Authors:  S Haraguchi; R A Good; M James-Yarish; G J Cianciolo; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 8.  A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways.

Authors:  Soichi Haraguchi; Robert A Good; Noorbibi K Day-Good
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

10.  Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association.

Authors:  B A Brody; E Hunter
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.